Literature DB >> 29675753

The Stomach as an Endocrine Organ: Expression of Key Modulatory Genes and Their Contribution to Obesity and Non-alcoholic Fatty Liver Disease (NAFLD).

Aybike Birerdinc1, Sasha Stoddard1, Zobair M Younossi2,3.   

Abstract

PURPOSE OF REVIEW: Obesity is currently seen in epidemic proportions globally and is one of the largest contributors to the development of NAFLD. The spectrum of NAFLD, particularly the progressive forms of NASH, is likely to become the leading cause of liver disease in the next decade. RECENT
FINDINGS: Soluble molecules, encoded by the stomach tissue, have been shown to have pleiotropic effects in both central and peripheral systems involved in energy homeostasis and obesity regulation. As such, the stomach is one of the important players in the complex, multi-system deregulation leading to obesity and NAFLD. The understanding of the stomach tissue as an active endocrine organ that contributes to the signaling milieu leading to the development of obesity and NAFLD is crucial.

Entities:  

Keywords:  Gene expression; Ghrelin; Gut/brain axis; Non-alcoholic fatty liver disease (NAFLD); Nonalcoholic steatohepatitis (NASH); Obesity

Mesh:

Substances:

Year:  2018        PMID: 29675753     DOI: 10.1007/s11894-018-0629-6

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  58 in total

1.  Nonalcoholic fatty liver disease is associated with cognitive function in adults.

Authors:  Sang Won Seo; Rebecca F Gottesman; Jeanne M Clark; Ruben Hernaez; Yoosoo Chang; Changsoo Kim; Kyoung Hwa Ha; Eliseo Guallar; Mariana Lazo
Journal:  Neurology       Date:  2016-02-24       Impact factor: 9.910

Review 2.  Opposite Regulation of Ghrelin and Glucagon-like Peptide-1 by Metabolite G-Protein-Coupled Receptors.

Authors:  M S Engelstoft; T W Schwartz
Journal:  Trends Endocrinol Metab       Date:  2016-07-27       Impact factor: 12.015

Review 3.  Ghrelin in gastrointestinal disease.

Authors:  Penny Jeffery; Victoria McDonald; Emma Tippett; Michael McGuckin
Journal:  Mol Cell Endocrinol       Date:  2011-03-30       Impact factor: 4.102

4.  Protection against diet-induced obesity and obesity- related insulin resistance in Group 1B PLA2-deficient mice.

Authors:  Kevin W Huggins; Amy C Boileau; David Y Hui
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-11       Impact factor: 4.310

5.  Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study.

Authors:  Maria Stepanova; Nila Rafiq; Zobair M Younossi
Journal:  Gut       Date:  2010-07-26       Impact factor: 23.059

6.  Gut hormone PYY(3-36) physiologically inhibits food intake.

Authors:  Rachel L Batterham; Michael A Cowley; Caroline J Small; Herbert Herzog; Mark A Cohen; Catherine L Dakin; Alison M Wren; Audrey E Brynes; Malcolm J Low; Mohammad A Ghatei; Roger D Cone; Stephen R Bloom
Journal:  Nature       Date:  2002-08-08       Impact factor: 49.962

Review 7.  Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ.

Authors:  Akio Inui; Akihiro Asakawa; Cyril Y Bowers; Giovanni Mantovani; Alessandro Laviano; Michael M Meguid; Mineko Fujimiya
Journal:  FASEB J       Date:  2004-03       Impact factor: 5.191

Review 8.  Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome.

Authors:  Chin Hee Kim; Zobair M Younossi
Journal:  Cleve Clin J Med       Date:  2008-10       Impact factor: 2.321

9.  Trefoil factor family member 2 (Tff2) KO mice are protected from high-fat diet-induced obesity.

Authors:  Maria Rita De Giorgio; Mayumi Yoshioka; Isabelle Riedl; Olivier Moreault; Rose-Guerline Cherizol; Aftab Ali Shah; Nikolaus Blin; Denis Richard; Jonny St-Amand
Journal:  Obesity (Silver Spring)       Date:  2013-06-11       Impact factor: 5.002

10.  Ghrelin Attenuates Liver Fibrosis through Regulation of TGF-β1 Expression and Autophagy.

Authors:  Yuqing Mao; Shaoren Zhang; Fujun Yu; Huanqing Li; Chuanyong Guo; Xiaoming Fan
Journal:  Int J Mol Sci       Date:  2015-09-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.